JOHNSON & JOHNSON |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 139.5 EUR | -0.11% |
|
+0.85% | -1.44% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 88.37B 81.69B 121B | Sales 2025 * | 90.78B 83.92B 124B | Capitalization | 364B 336B 497B |
|---|---|---|---|---|---|
| Net income 2024 * | 22.04B 20.37B 30.08B | Net income 2025 * | 23.09B 21.35B 31.52B | EV / Sales 2024 * | 4.04 x |
| Net cash position 2024 * | 7B 6.47B 9.55B | Net cash position 2025 * | 21.07B 19.48B 28.77B | EV / Sales 2025 * | 3.78 x |
| P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
15.9
x | Employees | 131,900 |
| Yield 2024 * |
3.19% | Yield 2025 * |
3.33% | Free-Float | 77.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on Johnson & Johnson
More recommendations
More press releases
| 1 day | -0.14% | ||
| 1 week | +0.85% | ||
| Current month | +2.45% | ||
| 1 month | -0.34% | ||
| 3 months | -3.88% | ||
| 6 months | +2.09% | ||
| Current year | -1.44% |
1 week
137.88
140.64
1 month
134.34142.16
Current year
134.34150.10
1 year
134.34161.20
3 years
133.12178.26
5 years
104.12178.26
10 years
72.55178.26
| Managers | Title | Age | Since |
|---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 88-12-31 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 97-12-31 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 19-11-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 19-04-24 |
D. Davis
BRD | Director/Board Member | 72 | 14-06-18 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 09-10-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 139.7 | +0.03% | 2 204 |
| 24-05-13 | 139.6 | +0.53% | 2,802 |
| 24-05-10 | 138.9 | +0.07% | 1,394 |
| 24-05-09 | 138.8 | +0.03% | 1,303 |
| 24-05-08 | 138.7 | +0.19% | 1,778 |
Delayed Quote Xetra, May 14, 2024 at 11:15 am
More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
151.2
USD
Average target price
173.3
USD
Spread / Average Target
+14.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.68% | 682B | |
| +30.35% | 586B | |
| +17.63% | 327B | |
| +3.78% | 285B | |
| +15.60% | 240B | |
| +10.32% | 209B | |
| -8.38% | 203B | |
| +7.02% | 165B | |
| -1.48% | 161B |
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock